JP2006501147A5 - - Google Patents

Download PDF

Info

Publication number
JP2006501147A5
JP2006501147A5 JP2003587325A JP2003587325A JP2006501147A5 JP 2006501147 A5 JP2006501147 A5 JP 2006501147A5 JP 2003587325 A JP2003587325 A JP 2003587325A JP 2003587325 A JP2003587325 A JP 2003587325A JP 2006501147 A5 JP2006501147 A5 JP 2006501147A5
Authority
JP
Japan
Prior art keywords
heat shock
shock protein
protein preparation
purified
purified heat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003587325A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006501147A (ja
Filing date
Publication date
Priority claimed from US10/322,312 external-priority patent/US6984389B2/en
Application filed filed Critical
Priority claimed from PCT/US2003/012802 external-priority patent/WO2003090686A2/en
Publication of JP2006501147A publication Critical patent/JP2006501147A/ja
Publication of JP2006501147A5 publication Critical patent/JP2006501147A5/ja
Pending legal-status Critical Current

Links

JP2003587325A 2002-04-25 2003-04-25 非ワクチン治療法の治療効果を改善するための熱ショックタンパク質の使用 Pending JP2006501147A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13196102A 2002-04-25 2002-04-25
US10/322,312 US6984389B2 (en) 2002-04-25 2002-12-16 Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
PCT/US2003/012802 WO2003090686A2 (en) 2002-04-25 2003-04-25 Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality

Publications (2)

Publication Number Publication Date
JP2006501147A JP2006501147A (ja) 2006-01-12
JP2006501147A5 true JP2006501147A5 (cg-RX-API-DMAC7.html) 2006-06-15

Family

ID=29272617

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003587325A Pending JP2006501147A (ja) 2002-04-25 2003-04-25 非ワクチン治療法の治療効果を改善するための熱ショックタンパク質の使用

Country Status (8)

Country Link
US (7) US20060079458A1 (cg-RX-API-DMAC7.html)
EP (1) EP1572083A4 (cg-RX-API-DMAC7.html)
JP (1) JP2006501147A (cg-RX-API-DMAC7.html)
AU (1) AU2003231098A1 (cg-RX-API-DMAC7.html)
CA (1) CA2483449A1 (cg-RX-API-DMAC7.html)
IL (1) IL164799A0 (cg-RX-API-DMAC7.html)
RU (1) RU2376029C2 (cg-RX-API-DMAC7.html)
WO (1) WO2003090686A2 (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7449557B2 (en) 2000-06-02 2008-11-11 University Of Connecticut Health Center Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
HK1079705A1 (zh) 2001-08-20 2006-04-13 University Of Connecticut Health Center 包含用於治疗癌症及感染性疾病的热休克蛋白或α2-巨球蛋白的组合物制备方法
AU2003231098A1 (en) 2002-04-25 2003-11-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
WO2004074454A2 (en) * 2003-02-20 2004-09-02 University Of Connecticut Health Center Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes
US7329495B2 (en) 2004-06-09 2008-02-12 Board Of Regents, The University Of Texas System Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors
KR20070072543A (ko) * 2004-09-27 2007-07-04 아스트라제네카 아베 Zd6474 및 이마티닙을 포함하는 병합법
GB0512091D0 (en) * 2005-06-14 2005-07-20 Novartis Ag Organic compounds
US20070098735A1 (en) * 2005-10-29 2007-05-03 Chandawarkar Rajiv Y Methods for the Elimination of Pathogens and Other Particulate Agents
ES2828739T3 (es) 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
WO2009114085A2 (en) 2008-03-03 2009-09-17 The University Of Miami Allogeneic cancer cell-based immunotherapy
JP5616336B2 (ja) 2008-06-26 2014-10-29 オルファザイム エーピーエスOrphazyme Aps 酵素活性の調節因子としてのHsp70の使用
BRPI1006897A2 (pt) 2009-07-06 2015-09-08 Akebia Therapeutics Inc compostos, composições e métodos de prevenção da metástase de células cancerosas.
US9634855B2 (en) 2010-05-13 2017-04-25 Alexander Poltorak Electronic personal interactive device that determines topics of interest using a conversational agent
US9662375B2 (en) 2010-11-30 2017-05-30 Orphazyme Aps Methods for increasing intracellular activity of Hsp70
MX363351B (es) 2011-10-13 2019-03-20 Aerpio Therapeutics Inc Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular.
AU2013222414B2 (en) 2012-02-21 2018-02-15 Cytonics Corporation Systems, compositions, and methods for transplantation
CN109608550B (zh) * 2012-12-05 2020-09-11 生控基因疫苗股份有限公司 用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白
JP6572201B2 (ja) 2013-03-15 2019-09-04 エアーピオ セラピューティクス インコーポレイテッド 眼疾患を処置するための組成物、製剤、および方法
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
WO2015031654A2 (en) 2013-08-28 2015-03-05 Cytonics Corporation Systems, compositions, and methods for transplantation and treating conditions
WO2015102680A2 (en) 2013-09-11 2015-07-09 The Board Of Trustees Of The Leland Stanford Junior University Methods and systems for beam intensity-modulation to facilitate rapid radiation therapies
FR3011850B1 (fr) 2013-10-15 2018-04-06 Cfl Biotech Vaccin therapeutique contre le cancer a base de proteines de stress rendues immunogenes
WO2015138882A1 (en) 2014-03-14 2015-09-17 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
US20150335679A1 (en) * 2014-05-20 2015-11-26 Kiromic, Llc Methods and Compositions for Treating Malignancies with Dendritic Cells
KR20160015076A (ko) 2014-07-30 2016-02-12 삼성전자주식회사 c-Met 저해제의 효능 예측을 위한 바이오마커 Hsp90
US9539245B2 (en) 2014-08-07 2017-01-10 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of Tie-2
KR102259232B1 (ko) 2014-08-25 2021-05-31 삼성전자주식회사 항 c-Met/항 Ang2 이중 특이 항체
US10709700B2 (en) 2014-09-15 2020-07-14 Orphazyme A/S Arimoclomol formulation
US10046047B2 (en) 2015-02-06 2018-08-14 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
EP3294324A1 (en) 2015-05-13 2018-03-21 Agenus Inc. Vaccines for treatment and prevention of cancer
CN113713101B (zh) 2015-09-23 2023-07-28 视点制药公司 用tie-2的激活剂治疗眼内压的方法
WO2017178029A1 (en) 2016-04-13 2017-10-19 Orphazyme Aps Heat shock proteins and cholesterol homeostasis
ES2831764T3 (es) 2016-04-29 2021-06-09 Orphazyme As Arimoclomol para el tratamiento de trastornos asociados a glucocerebrosidasa
US11666649B2 (en) 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
WO2018187260A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
US11173325B2 (en) 2017-07-21 2021-11-16 Varian Medical Systems, Inc. Methods of use of ultra-high dose rate radiation and therapeutic agent
EP3784688A2 (en) 2018-04-26 2021-03-03 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
EP4247792A1 (en) 2020-11-19 2023-09-27 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5736146A (en) * 1992-07-30 1998-04-07 Yeda Research And Development Co. Ltd. Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them
AU5873994A (en) 1992-12-18 1994-07-19 Duke University Immune response modulator complex, and uses thereof
NZ266527A (en) 1993-06-08 1999-10-28 Cancer Res Campaign Tech Alkylguanine derivatives and pharmaceutical compositions
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5997873A (en) * 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5869058A (en) * 1994-05-25 1999-02-09 Yeda Research And Development Co. Ltd. Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
DK0765386T3 (en) 1994-06-14 2015-01-26 Univ Leland Stanford Junior Methods for T cell activation in vivo with antigen-incubated dendritic cells
US5789448A (en) * 1994-07-27 1998-08-04 Mitsubishi Chemical Corporation Benzoylethylene derivative
JP4163253B2 (ja) 1995-08-18 2008-10-08 スローン−ケッタリング インスティチュート フォー キャンサー リサーチ 熱ショックタンパク質に基づくワクチンおよび免疫療法
EP0851765A4 (en) * 1995-09-13 2000-01-19 Univ Fordham THERAPEUTIC AND PROPHYLACTIC PROCESSES THAT USE HEAT SHOCK PROTEINS
US5985270A (en) * 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5935576A (en) * 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5837251A (en) * 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US5939098A (en) 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
US5830464A (en) * 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
US6017540A (en) * 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
AU742999B2 (en) * 1997-08-20 2002-01-17 Warner-Lambert Company Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
JPH1180131A (ja) * 1997-09-01 1999-03-26 Mitsubishi Chem Corp エチニルピリミジン誘導体
WO1999022761A1 (en) * 1997-10-31 1999-05-14 Sloan-Kettering Institute For Cancer Research Conjugate heat shock protein-binding peptides
WO1999049881A2 (de) * 1998-03-27 1999-10-07 Gabriele Multhoff Verwendung von hsp70 protein
US6403092B1 (en) 1998-04-01 2002-06-11 Duke University Immune response modulator alpha-2 macroglobulin complex
WO1999055689A1 (en) * 1998-04-24 1999-11-04 Kyowa Hakko Kogyo Co., Ltd. Radicicol derivatives
GB9810423D0 (en) 1998-05-15 1998-07-15 Cancer Res Campaign Tech Ionizing radiation or diathermy-switched gene therapy vectors and their use in antitumour therapy
US6251886B1 (en) 1998-12-07 2001-06-26 Schering Corporation Methods of using temozolomide in the treatment of cancers
EP1165144A2 (en) 1999-03-15 2002-01-02 Introgen Therapeutics, Inc. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
EP1161258A1 (en) 1999-03-17 2001-12-12 EntreMed, Inc. Compositions and methods of use of ldl-like receptor ligands for the treatment of cancer and angiogenic-based disease
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
US6358954B1 (en) * 1999-11-09 2002-03-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same
JP3273777B2 (ja) * 2000-04-07 2002-04-15 武田薬品工業株式会社 複素環化合物、その製造法および用途
PE20011178A1 (es) * 2000-04-07 2001-11-19 Takeda Chemical Industries Ltd Compuestos heterociclicos y su produccion
US7449557B2 (en) 2000-06-02 2008-11-11 University Of Connecticut Health Center Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
AU2001277961A1 (en) * 2000-08-07 2002-02-18 Antigenics, Llc Compositions comprising heat shock proteins or alpha(2)macroglobulin, antigenic molecules and saponins, and methods of use thereof
ATE453718T1 (de) 2000-08-29 2010-01-15 Genentech Inc Verfahren zur verbesserung von krebstherapie
WO2002022133A1 (en) 2000-09-12 2002-03-21 Virginia Commonwealth University Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents
AU2001292674A1 (en) * 2000-09-15 2002-04-29 University Of Connecticut Health Center Improved formulations using heat shock/stress protein-peptide complexes
US20020172682A1 (en) * 2000-10-20 2002-11-21 University Of Connecticut Health Center Using heat shock proteins to increase immune response
US7132109B1 (en) 2000-10-20 2006-11-07 University Of Connecticut Health Center Using heat shock proteins to increase immune response
RU2192884C2 (ru) * 2000-11-09 2002-11-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Вакцина для стимуляции противоопухолевого иммунитета
FR2835746B1 (fr) 2002-02-14 2006-05-26 Vincience Composition cosmetique ou pharmaceutique comprenant des hsp et des retinoides, procede de traitement et utilisation
EP1578773A3 (en) * 2002-02-28 2005-12-14 Antigenics Inc. Methods and products based on oligomerization of stress proteins
AU2003231098A1 (en) 2002-04-25 2003-11-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
US6984389B2 (en) 2002-04-25 2006-01-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
CA2483925A1 (en) * 2002-05-02 2004-04-29 University Of Connecticut Health Center Using heat shock proteins and alpha-2-macroglobulins to increase immune response to vaccines comprising heat shock protein-peptide complexes or alpha-2-macroglobulin-peptide complexes
CN1665533A (zh) * 2002-05-02 2005-09-07 康涅狄格大学健康中心 热激蛋白用于增强抗体疗法功效的用途
JP2006514088A (ja) * 2003-02-20 2006-04-27 ユニバーシティー オブ コネティカット ヘルス センター 癌および感染症の治療における熱ショックタンパク質またはα−2−マクログロブリンを含む組成物の使用方法
US7446124B2 (en) 2004-07-09 2008-11-04 Prolx Pharmaceuticals Corp. Wortmannin analogs and methods of using same in combination with chemotherapeutic agents

Similar Documents

Publication Publication Date Title
Goldman et al. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase [see comments]
JP6322413B2 (ja) 改善されたがん治療のための局所および全身性免疫修飾療法の組み合わせ
RU2376029C2 (ru) Применение белков теплового шока для улучшения терапевтического эффекта невакцинного лечебного воздействия
CN106414493A (zh) 包含突变的ras肽和化疗剂的肽疫苗
JP2022533578A5 (cg-RX-API-DMAC7.html)
JP2020023547A (ja) 空間配置が変化した組換えインターフェロンを用いる腫瘍治療の方法
JP2002535249A (ja) 腫瘍を治療する放射線療法及びcox−2阻害剤の組合せ療法。
JP2023513704A5 (cg-RX-API-DMAC7.html)
JP2022534118A5 (cg-RX-API-DMAC7.html)
Kovalchin et al. Determinants of efficacy of immunotherapy with tumor-derived heat shock protein gp96
van der Veldt et al. Targeted therapy for renal cell cancer: current perspectives
EA013813B1 (ru) Применение иматиниба для лечения гепатита с
Jarnagin et al. Neoadjuvant interleukin-12 immunogene therapy protects against cancer recurrence after liver resection in an animal model
Heng et al. Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions
EE04966B1 (et) (-)-5-(3-klorofenl)-alfa-(4-klorofenl)-alfa-(1-metl-1H-imidasool-5-l)tetrasolo -[1,5-a]kinasoliin-7-metaanamiin, selle valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja meetodselle valmistamiseks
JP2025508548A5 (cg-RX-API-DMAC7.html)
US20230065168A1 (en) Vismodegib in combination with a replication-deficient type 5 adenovirus for expression of interferon gamma for the treatment of skin cancer
US20110281813A1 (en) Method of treating c-kit positive relapsed acute myeloid leukemia
Kuhn et al. Targeting tumorangiogenesis in lung cancer by suppression of VEGF and its receptor-results from clinical trials and novel experimental approaches
JP2023519580A5 (cg-RX-API-DMAC7.html)
RU2105567C1 (ru) Способ лечения злокачественных опухолей
Giordano et al. New dimensions in cancer biology and therapy
CN1537012A (zh) 长五亚基环ptx3在治疗fgf-8介导的肿瘤疾病中的应用
Urba et al. Organ preservation in multimodality therapy of head and neck cancer
JP2012025734A (ja) 骨髄異形性症候群を治療するための組成物および方法